secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001564590-21-055698
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q3 2021: cash $290.5M; BDC-1001 interim data at ESMO I-O in Dec
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $290.5M at Sep 30, 2021; plus $5M upfront from Innovent in Oct.
- Operating loss $23.5M in Q3 2021 vs $12.4M in Q3 2020; R&D expenses rose to $19.3M.
- BDC-1001 Phase 1/2 monotherapy interim data (>50 patients) to be presented at ESMO I-O Congress in Dec 2021.
- Combination dose escalation with Opdivo expected to start Q4 2021; collaboration with Innovent for up to 3 ISACs.
- Cash expected to fund operations through end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000156459021055698/0001564590-21-055698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000156459021055698/bolt-8k_20211109.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer